CClinicalTrials.gg
CompletedNCT04780958Updated Mar 5, 2021

Retinol Status in Preterm Infants and Mothers

An interventional study of Serum retinol and RBP levels were determined by enzyme-linked immunosorbent assay. in Vitamin A Deficiency, sponsored by Ataturk University. Completed at 1 site in Turkey. Open to participants aged 5 Minutes to 10 Minutes, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-05.

Sponsored by Ataturk University · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Not applicable
Ages
5 Minutes to 10 Minutes
Sex
All
01

Study summary

Retinol and retinol binding protein were studied in the umbilical cord blood of 44 preterm infants with gestation age of \< 30 weeks. Serum retinol and RBP levels were determined by enzyme-linked immunosorbent assay. The rate of transplacental retinol passage was calculated. The demographic data of mother and baby, vitamin use in the mother, antenatal steroid application and diseases diagnosed during pregnancy were recorded. An evaluation was made of the retinol, RBP and factors of the mother and baby affecting the transplacental retinol passage. The relationship between retinol and retinol binding protein levels and neonatal mortality and morbidity was investigated.

Read the detailed description

Study Population Babies born at this hospital with a gestational week of \<30 were included in the study. Patients were excluded in the presence of a major abnormality or known congenital metabolic disease in the mother or baby, and the presence of chronic liver, kidney or gastrointestinal system disease in the mother, or if the family did not give consent. A record was made of the gender and birth weight of the babies and gestation week, maternal age, gravidity, status of vitamin intake and use of vitamin A during pregnancy, and antenatal steroid administration in the mothers. A record was made of the presence of early membrane rupture (EMR) diagnosed during the present pregnancy of the mother, preeclampsia/eclampsia, pregnancy-induced hypertension, urinary infection, gestational diabetes mellitus and anemia, if present. We recorded also neonatal mortality and morbidity such as respiratory distress syndrome, retinopathy of prematurity, necrotizing enterocolitis, intraventricular hemorrhage, bronchopulmonary dysplasia,

Sampling and Test Study Method Umbilical cord blood was drawn at birth in all babies included in the study by experienced individuals using a vacutainer. Approximately 6 ml of venous blood was also drawn from the antecubital region of the mothers immediately after the birth in a biochemistry tube, and centrifuged for 10 minutes at 4500 rpm after the completion of coagulation, and the sera were separated. Serum samples were frozen and stored at -80° until the analysis was performed. For the analysis, serum samples were thawed in appropriate circumstances and all analyzes were performed at the Medical Biochemistry Laboratory of Atatürk University at a single session.

In the serum samples, the retinol levels were analyzed using ELISA kits from the Bioassay Technology Laboratory ( E1548 Hu Jiaxing, Zhejiang, China), RBP levels were analyzed using ELISA kits of Elabscience (E-EL-H1581 Texas USA) following the standard protocol suggested by the manufacturer at the Dynex automated ELISA reading device (Dynex Technologies Headquarters, Chantilly, USA). The measurement range of the kit for retinol and RBP was 2ng/ml- 800 ng/ml and 0,07 - 100 ng/mL, respectively.

The formula "umbilical cord retinol/maternal retinol x100" was used for the calculation of placental retinol passage rate in order to show the percentage of maternal retinol passing to the umbilical cord .

Retinol deficiency was evaluated according to the WHO data. A level of \< 20 µg/dl was accepted as a deficiency. The level of deficiency was accepted as \< 200 ng/ml since the unit used in this present study was ng/ml.

02

Conditions studied

  • Vitamin A Deficiency

Keywords

  • Retinol
  • Preterm infant
  • Morbidity
  • Placenta
03

Who can participate

Ages eligible
5 Minutes to 10 Minutes
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • Babies born l with a gestational week of \<30 and their mothers were included in the study.

Exclusion criteria

Exclusion Criteria:

  • Patients were excluded in the presence of a major abnormality or known congenital metabolic disease in the mother or baby, and the presence of chronic liver, kidney or gastrointestinal system disease in the mother, or if the family did not give consent.
04

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
44 participants (actual)

Study arms

  • Other
    Study population

    During the study period, babies born at this hospital with a gestational week of \<30 were included .

    Other: Serum retinol and RBP levels were determined by enzyme-linked immunosorbent assay.

Interventions

  • OtherSerum retinol and RBP levels were determined by enzyme-linked immunosorbent assay.

    Umbilical cord blood was drawn at birth in all babies included in the study by experienced individuals using a vacutainer. Approximately 6 ml of venous blood was also drawn from the antecubital region of the mothers immediately after the birth in a biochemistry tube.In the serum samples, the retinol levels were analyzed using ELISA kits from the Bioassay Technology Laboratory ( E1548 Hu Jiaxing, Zhejiang, China), RBP levels were analyzed using ELISA kits of Elabscience (E-EL-H1581 Texas USA) following the standard protocol suggested by the manufacturer at the Dynex automated ELISA reading device (Dynex Technologies Headquarters, Chantilly, USA)

05

What researchers measure

Primary outcomes

  1. Retinol deficiency status in preterm infants and mothers

    Number of Participants with retinol deficiency was evaluated according to the WHO data. Concentration of retinol level \< 20 µg/dl was accepted as a deficiency. The level of deficiency was accepted as \< 200 ng/ml since the unit used in this present study was ng/ml.

    Time frame: 4 months

  2. Retinol deficiency in preterm infants with respiratory distress syndrome

    Numbers of preterm infants with respiratory distress syndrome as assessed accordingly European Consensus Respiratory Distress Syndrome, and have been reported retinol deficiency according to WHO data .

    Time frame: 3 months

  3. Retinol deficiency in preterm infants with retinopathy of prematurity

    Numbers of preterm infants with retinopathy of prematurity as assessed accordingly the International Classification of Retinopathy of Prematurity, and have been reported retinol deficiency according to WHO data .

    Time frame: 3 months

  4. Retinol deficiency in preterm infants with bronchopulmonary dysplasia

    Numbers of preterm infants with bronchopulmonary dysplasia as assessed accordingly the 2001 National Institutes of Health (NIH) Workshop, and have been reported retinol deficiency according to WHO data .

    Time frame: 3 months

  5. Retinol deficiency in preterm infants with intraventricular hemorrhage

    Numbers of preterm infants with intraventricular hemorrhage as assessed accordingly Grading System for Neonatal Intraventricular Hemorrhage, and have been reported retinol deficiency according to WHO data .

    Time frame: 3 months

  6. Mortality of preterm infants

    It was planned to check mortality rate in preterm infants with retinol deficiency. Retinol deficiency rate was calculated accordingly Who data.

    Time frame: 3 months

06

Study locations

1 site
  • Ataturk University Medical Faculty
    Erzurum, 25100, Turkey
07

Registry details

Key details

Study ID
NCT04780958
Lead sponsor
Ataturk University
Collaborators
Scientific Research Fund of Atatürk University
Responsible party
Kadir Şerafettin Tekgündüz (Assoc. Prof., Ataturk University) — Principal investigator
First posted
Mar 4, 2021
Start date
Jun 1, 2020
Primary completion
Jan 31, 2021
Completion
Jan 31, 2021
Last update
Mar 5, 2021

Study contacts

Kadir Ş Tekgündüz, Assoc.Prof
study director · Ataturk University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion